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Introduction: We hypothesized that serum levels of C-X-C motif chemokine 13 (CXCL13), a B-cell chemokine, would
delineate a subset of rheumatoid arthritis (RA) patients characterized by increased humoral immunity.
Methods: Serum from patients with established RA (the Dartmouth RA Cohort) was analyzed for CXCL13,
rheumatoid factor (RF) levels, anticitrullinated peptide/protein antibody (ACPA) and total immunoglobulin G (IgG);
other parameters were obtained by chart review. A confirmatory analysis was performed using samples from the
Sherbrooke Early Undifferentiated PolyArthritis (EUPA) Cohort. The Wilcoxon rank-sum test, a t-test and Spearman’s
correlation analysis were utilized to determine relationships between variables.
Results: In both the Dartmouth and Sherbrooke cohorts, CXCL13 levels were selectively increased in seropositive
relative to seronegative RA patients (P = 0.0002 and P < 0.0001 for the respective cohorts), with a strong correlation
to both immunoglobulin M (IgM) and IgA RF levels (P < 0.0001). There was a weaker relationship to ACPA titers
(P = 0.03 and P = 0.006, respectively) and total IgG (P = 0.02 and P = 0.14, respectively). No relationship was seen
with regard to age, sex, shared epitope status or inclusion high-sensitivity C-reactive protein (hsCRP) in either
cohort or regarding the presence of baseline erosions in the Sherbrooke Cohort, whereas a modest relationship
with Disease Activity Score in 28 joints CRP (DAS28-CRP) was seen in the Dartmouth cohort but not the Sherbrooke
cohort.
Conclusion: Using both established and early RA cohorts, marked elevations of serum CXCL13 levels resided nearly
completely within the seropositive population. CXCL13 levels exhibited a strong relationship with RF, whereas the
association with clinical parameters (age, sex, DAS28-CRP and erosions) or other serologic markers (ACPA and IgG)
was either much weaker or absent. Elevated serum CXCL13 levels may identify a subset of seropositive RA patients
whose disease is shaped by or responsive to RF production.Introduction
Seropositive rheumatoid arthritis (RA) is an inflam-
matory disease characterized by autoantibodies (im-
munoglobulin G (IgG) anticitrullinated peptide/protein
antibodies (ACPAs) and rheumatoid factor (RF)). These
autoantibodies can appear years before the onset of
clinical disease and are strongly linked to the human* Correspondence: jonathan.d.jones@dartmouth.edu
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II DR β1 (HLA-DRB1) alleles containing the shared epi-
tope [1]. The presence of IgG ACPAs and IgA-RF indicates
that antibody heavy-chain class-switching has occurred,
which is typically associated with T-cell–dependent B-cell
maturation and differentiation [2,3].
An important element of T-cell–dependent B cell mat-
uration and differentiation is the formation of lymphoid
follicles and germinal centers. Murine studies indicate the
interaction of the C-X-C motif chemokine 13 (CXCL13)
with C-X-C chemokine receptor type 5 (CXCR5) promotestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patients in the Dartmouth RA Cohorta
Patient demographics (N = 193) Seronegative Seropositive
Number of patients (%) 30 (16%) 163 (84%)
Average age, yr (range) 55.6 (29 to 72) 57.9 (19 to 92)
Females, n (%) 24 (80%) 115 (71%)
RA duration <2 yr 10 (33%) 41 (25%)
SE status, n 14 116
SE alleles = 0 7 22
SE alleles = 1 7 56
SE alleles = 2 0 38
C4 status, n 14 111
C4 copies <4 9 30
C4 copies ≥4 5 81
Medication history, n
No DMARDs 9 36
Nonbiologic DMARDs 10 54
TNF inhibitors 4 42
Other biologics 7b 31c
aC4, Complement 4; DMARD, Disease-modifying antirheumatic drug; RA,
Rheumatoid arthritis; SE, Shared epitope; TNF, Tumor necrosis factor.
bAbatacept (n = 1) and rituximab (n = 6). cAbatacept (n = 2), rituximab
(n = 27), tocilizumab (n = 1) and tofacitinib (n = 1).
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follicular T cells to the lymphoid follicle [4-6]. Thus, it
seems reasonable to posit that CXCL13 plays a role in the
development of both IgG ACPAs and IgA-RF prior to the
development of clinical signs and symptoms.
In addition to the development of autoantibodies in the
preclinical phase, CXCL13 has been associated with
synovial inflammation in RA. A series of observations
has established its production by multiple cell types in
rheumatoid synovium, frequently in association with the
formation of lymphoid follicular structures, including
synovial T cells (but not T follicular cells) [7], monocytes/
macrophages [8] and follicular dendritic cells, endothelial
cells and synovial fibroblasts [9].
In addition to its synovial production in RA, elevated
serum levels of CXCL13 have been observed and were
reported to be 1.7× higher in one small study of patients
with active relative to quiescent disease [10]. Rosengren
et al. subsequently established the presence of a strong
relationship between synovial CXCL13 mRNA expres-
sion and serum CXCL13 level in a cohort of patients
with long-standing RA [11]. Thus, synovial production
appears to account for increased serum CXCL13 levels
rather than serum CXCL13 elevation arising from a sys-
temic reaction to joint inflammation.
Given those data, we hypothesized that serum CXCL13
levels would reflect the impact of CXCL13 on synovial
inflammation and the shaping of the clinical and serolo-
gic phenotype. We specifically wished to determine if
CXCL13 levels identify a subset of RA patients, perhaps
indicating a greater role of humoral immunity in disease
pathogenesis. We undertook a cross-sectional analysis of
circulating serum CXCL13 levels in RA patients followed
at the Dartmouth-Hitchcock Medical Center. In this co-
hort, we observed that CXCL13 expression was much
higher in seropositive than seronegative RA patients. In
addition, we observed that this relationship correlated
most strongly with RF and not with ACPA. Subsequently,
we saw identical relationships in an early RA cohort. We
performed genetic, serologic and clinical analyses, which
indicated that serum CXCL13 levels may identify a novel
(and abundant) subpopulation of seropositive RA. Ad-




The Dartmouth RA Cohort consists of patients recruited
from the Dartmouth-Hitchcock Medical Center Rheuma-
tology Clinic (Lebanon, NH, USA) who have established
RA defined according to the American College of Rheu-
matology (ACR) 1987 revised criteria [12]. This cohort
represents a patient population with established RA whose
disease duration extends, in some cases, longer than 20years (Table 1). Approval for this study was obtained from
the Committee for the Protection of Human Subjects at
Dartmouth College, and the patients provided their in-
formed, signed consent to participate. Age and sex, disease
duration, medication history, smoking status, seroposi-
tivity (determined by clinical laboratory determination of
RF >14 IU/ml using immunoturbidimetric measurement
(Roche Diagnostics, Indianapolis, IN, USA) and/or anti–
cyclic citrullinated peptide 2 (anti-CCP2) >5.0 U/ml by
enzyme-linked immunosorbent assay (ELISA) (DiaSorin,
Saluggia, Italy)) and high-sensitivity C-reactive protein
(hsCRP) levels were recorded, and serum and DNA were
collected. In some cases, Disease Activity Score in 28
joints CRP (DAS28-CRP) and Clinical Disease Activity
Index (CDAI) scores were available from the clinical
charts.
The confirmatory cohort consists of a subset of the pa-
tients recruited from Sherbrooke, QC, Canada, as part
of the longitudinal Early Undifferentiated Polyarthritis
(EUPA) Cohort. This cohort varies from the Dartmouth
RA Cohort in that it represents an early arthritis popula-
tion, contains a greater proportion of seronegative patients
and has predominantly patients who were DMARD- and
corticosteroid-naïve at the time of inclusion. Cohort inclu-
sion criteria included age ≥18 years, disease duration bet-
ween 1 and 12 months and swollen joint count of three or
more. In the subset reported herein, all RA patients ful-
filled the 1987 ACR revised criteria. Seropositivity was de-
fined as both an RF titer ≥40 IU/ml measured using
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CCP2 >20 U/ml using QUANTA Lite (Inova Diagnostics,
San Diego, CA, USA), present concurrently at least once.
Seronegativity was defined as negative RF and anti-CCP2
at all the visits. This subset was chosen randomly from
among the Sherbrooke EUPA Cohort, with samples
matched only for serostatus. The patients provided their
signed, informed consent to participate, and study ap-
proval was obtained from the Sherbrooke University
Hospital Centre Institutional Review Board. Information
gathered at enrollment included demographic details such
as age, sex and time since onset of arthritis, as well as cli-
nical details such as DAS28-CRP score, radiologic Sharp
score and RF and ACPA status (Table 2).
Serum analysis
Patient serum was stored at −80°C (Dartmouth RA Cohort)
or −20°C (Sherbrooke EUPA Cohort) until analysis.
CXCL13 levels were measured by ELISA according to
the manufacturer’s instructions (Human CXCL13/BLC/
BCA-1 DuoSet; R&D Systems, Minneapolis, MN, USA).
Several samples were kept and repetitively measured over
the course of 3 weeks at 4°C, with no change in CXCL13
levels compared to freshly thawed serum. Serum samples
were diluted 1:100, but the ELISA was repeated at a serum
dilution of 1:10 in cases where low values were obtained.
In six RF-positive patient samples, HeteroBlock reagent
(Omega Biologicals, Bozeman, MT, USA) was titrated into
the assay to eradicate the potential for false-positiveTable 2 Recent-onset rheumatoid arthritis patients in the
Sherbrooke Early Undifferentiated PolyArthritis Cohorta
Patient demographics (N = 339) Seronegative Seropositive
Number of patients (%) 166 (49%) 173 (51%)
Average age, yr (range) 54.2 (21 to 92) 65.6 (19 to 87)
Females, n (%) 107 (64) 105 (61)
Symptom duration, yr 0.44 0.45
SE status, n 120 132
SE alleles = 0 75 43
SE alleles = 1 44 59
SE alleles = 2 1 30
Mean DAS28-CRP (±SD) 5.10 (1.47) 5.04 (1.44)
Mean CRP mg/L (±SD) 24.4 (33.9) 26.6 (35.6)
Mean Sharp score erosions (±SD) 2.9 (6.1) 3.8 (7.0)
Mean Sharp score narrowing (±SD) 3.4 (6.1) 2.2 (4.1)
Tender joints 10.4 9.8
Swollen joints 10.5 10.2
Patient VAS score (100-mm scale) 54.2 53.9
aCRP, C-reactive protein; DAS28-CRP, Disease Activity Score in 28 joints C-reactive
protein; SE, Shared epitope; VAS, Visual Analogue Scale. Seronegative vs
seropositive analysis: Symptom duration, P = 0.85; DAS28-CRP, P = 0.72; CRP,
P = 0.56; Sharp score erosions, P = 0.28; Sharp score narrowing, P = 0.09.CXCL13 results due to the heterophilic activity of RF. We
noticed that our range of CXCL13 levels was greater than
levels reported elsewhere in the literature, so we con-
firmed the results in the Dartmouth RA Cohort using
a premade ELISA kit from the same company (R&D
Systems), which showed minimal variation from the ori-
ginal values we obtained (r = 0.95).
Total levels of IgG were measured by ELISA (Immu-
nology Consultants Laboratory, Portland, OR, USA), as
were IgM RF levels (TheraTest Laboratories, Lombard,
IL, USA) and IgA RF levels (Inova Diagnostics). In the
Dartmouth RA Cohort, we additionally measured serum
levels of IgG ACPA using a human QUANTA Lite CCP3
IgG ELISA kit (Inova Diagnostics). All analyses were done
on the same sample or with samples from an aliquot iden-
tical to the sample used to measure CXCL13. The one ex-
ception was the measurement of anti-CCP2 levels (Inova
Diagnostics/EUROIMMUN US, Morris Plains, NJ, USA)
in the Sherbrooke EUPA Cohort, as it was measured
either simultaneously with or within a few weeks after the
serum collection used for the CXCL13 assay.DNA analysis
In the Dartmouth RA Cohort, HLA-DRB1 status (shared
epitope) was obtained previously [13] through the American
Red Cross Penn-Jersey Blood Services Region. Complement
4 (C4) allele copy number was also obtained as described
previously [13] by Southern blot analysis, with confirmation
by RT-PCR. HLA-DRB1 typing in the Sherbrooke EUPA
Cohort was determined using sequence-specific primer
PCR techniques as previously described [14].Statistical analysis
Statistical analysis was performed using STATA software
version 12.1 (StataCorp, College Station, TX, USA).
CXCL13, hsCRP and IgA RF levels were log-transformed
because of the wide range and non-normal distribution of
the data. Comparisons of two means were carried out
by independent Student’s t-test or by Wilcoxon rank-sum
test for non-normal distributions. Pearson correlation or
Spearman correlation (in non-normal distributions) were
used for analysis of log-transformed CXCL13 and other
measures, such as IgM RF, ACPA, total IgG, age, hsCRP,
DAS28-CRP, CDAI and erosions. For additional analysis
of CXCL13 relationships to RF and ACPA, CXCL13 values
from seropositive patients were divided into tertiles. The
lower and upper cutoffs for the Dartmouth RA Cohort
were 160 and 400 pg/ml, respectively. For the Sherbrooke
EUPA Cohort, the lower and upper cutoffs were 150 and
1100 pg/ml, respectively. Because of clear overlap of RF
values of the lower two CXCL13 tertiles, these values were
combined for comparison to the highest tertile. Two-
tailed P values <0.05 were considered significant.
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CXCL13 is elevated in seropositive rheumatoid arthritis
patients and correlates with immunoglobulin M
rheumatoid factor
The Dartmouth RA Cohort (N = 193) represents an
established RA cohort with a variation in disease du-
ration from <1 year to >20 years (Table 1). We first ana-
lyzed serum CXCL13 levels in seronegative patients in
relation to seropositive patients, as determined by the cli-
nical laboratory data and chart history. Owing to the range
of CXCL13 levels obtained (0 to >53,000 pg/ml) and the
non-normal distributions, the data were log-transformed
(log CXCL13). We identified a significant elevation in log
CXCL13 levels in seropositive patients (by independent
Student’s t-test), with a geometric mean values (95% CI) of
93 pg/ml in seronegatives (71.3 to 123.9) and 331 pg/ml in
seropositives (250.0 to 430.5) (P = 0.0002) (Figure 1A).
The addition of HeteroBlock did not alter the results, thus
confirming that these findings were not due to the pre-
sence of RF in the seropositive sera (data not shown).
Serum IgM RF and IgG ACPA levels were measured
in the seropositive patients and evaluated by Spearman
correlation in relation to log CXCL13 levels. We found
a highly significant relationship to IgM RF (r = 0.45,
P < 0.0001) (Figure 1B), with a much weaker relationshipFigure 1 Scatterplots illustrate strong correlation of serum CXCL13 w
the Dartmouth RA Cohort. (A) Log-transformed C-X-C motif chemokine 13
rheumatoid arthritis (RA) patients by t-test (seropositive (n = 163), geometric m
geometric mean (95% CI) 93.3 pg/ml (71.3 to 123.9); P = 0.0002). (B) The log-t
rheumatoid factor (RF) levels when evaluated by Spearman correlation (P < 0
CXCL13 tertile (third tertile) to the first and second tertiles by Wilcoxon rank-s
(third-tertile IgM RF: mean = 182 ± 59 IU/ml; first- and second-tertile IgM RF: m
to IgG anticitrullinated peptide/protein antibody (ACPA) (P = 0.03). *P < 0.05.to IgG ACPA (r = 0.17, P = 0.03) (Figure 1D). Of the 163
seropositive patients, 7 patients (4.3%) were positive for
IgG ACPA but negative for IgM RF, and 8 patients (4.9%)
were negative for IgG ACPA but positive for IgM RF.
Evaluation of the CXCL13 values of these single-positive
samples did not differ from the remaining double-positive
samples (data not shown). Tertile analysis of CXCL13
values confirmed that IgM RF was higher in the third than
in the first and second tertiles (mean = 182 ± 59 vs 113 ±
74 U/ml; P < 0.0001) (Figure 1C) but that IgG ACPA was
not (mean = 511 ± 319 vs. 419 ± 339 U/ml; P = 0.09) (data
not shown), as determined by Wilcoxon rank-sum test.
Evaluation of log CXCL13 levels in relation to total IgG
levels showed a weak but statistically significant relation-
ship (r = 0.18, P = 0.02) (data not shown).
We examined the potential relationship of log CXCL13
levels to genetic markers (shared epitope status and com-
plement C4B gene copy number deficiency) associated with
autoantibody positivity in RA [13,15]. We saw no relation-
ship between log CXCL13 levels in seropositive RA patients
(n = 115 patients with HLA-DRB1 determination) in the
presence or absence of the shared epitope (P = 0.91) (data
not shown). Similarly, no relationship was seen (n = 111
patients with C4 (please italicize) gene copy number
determination) with C4B gene copy number deficiencyith seropositivity and immunoglobulin M rheumatoid factor in
(CXCL13) values are higher in seropositive compared to seronegative
ean (95% CI) = 331.1 pg/ml (250.0 to 430.5); seronegative (n = 30),
ransformed CXCL13 values of seropositive patients increase with higher
.0001). (C) Tertile analysis of seropositive patients comparing the highest
um test identifies a strong relationship with immunoglobulin M (IgM) RF
ean = 113 ± 74 IU/ml; P < 0.0001). (D) CXCL13 has a weaker relationship
Diagonal lines represent line of best fit.
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ciency, defined as C4 gene copy number <4 (P = 0.35)
(data not shown).
CXCL13 relationships to other serologic and clinical
features
Within this cross-sectional analysis, we examined the rela-
tionship of CXCL13 levels in relation to laboratory-
reported hsCRP levels at the time of sample collection
(n = 123 seropositive patients) and various clinical assess-
ments of disease activity, namely, DAS28-CRP and CDAI.
Log-transformed hsCRP (log CRP) and log CXCL13
showed only a trend toward significance (P = 0.07)
(Figure 2A). Simultaneous measures of DAS28-CRP and
CDAI on 23 and 22 seropositive patients, respectively,
were available. The DAS28-CRP association was shown to
be significant (r = 0.52, P = 0.01) (Figure 2B), whereas the
CDAI showed only a trend toward a relationship to log
CXCL13 (r = 0.38, P = 0.08) (data not shown). Further
analyses included comparing log CXCL13 to age and sex,
but the results were unremarkable (P = 0.28 and P = 0.34
respectively) (data not shown). Additionally, we found no
relationship of log CXCL13 to smoking status as defined
by never-smokers, past smokers and current smokers
(P = 0.47).Figure 2 Scatterplots show minimal or no relationship of serum CXCL
in 28 joints C-reactive protein in the seropositive groups of the Dartm
PolyArthritis Cohort. (A) In the Dartmouth RA Cohort, correlation analysis
high-sensitivity C-reactive protein (LogCRP) does not show a relationship (n =
CXCL13 has a modest relationship with Disease Activity Score in 28 joints CRP
arthritis (RA) patients from the Sherbrooke Early Undifferentiated PolyArthritis
LogCRP (n = 173, P = 0.08). (D) In the recent-onset RA patients from the Sher
and DAS28-CRP (n = 170, P = 0.28). Diagonal lines represent lines of best fit.Relationships between CXCL13 and antibody levels in an
early rheumatoid arthritis cohort
We compared our findings in an established RA cohort to
that of a well-characterized early RA cohort (the Sher-
brooke EUPA Cohort) to address any potential confoun-
ding by current or past therapy. This cohort consisted of a
nearly equal number of seronegative and seropositive
patients (n = 166 and 173, respectively) with an average
disease duration of approximately 5 months (Table 2).
As with established RA, a strong relationship with log
CXCL13 levels and seropositivity had already been seen at
the inclusion visit (P < 0.0001) (Figure 3A) with a geome-
tric mean (95% CI) of 50.1 pg/ml (35.0 to 78.0) in seroneg-
atives and 323.6 pg/ml (223.9 to 477.5) in seropositives.
Similarly, we observed a strong relationship in the sero-
positive patients when log CXCL13 levels were evaluated
by Spearman correlation analysis against IgM RF levels
(r = 0.54, P < 0.0001) (Figure 3B) as well as by tertile
analysis (P < 0.0001) (Figure 3C). In comparison to the pa-
tients with established RA in the Dartmouth RA Cohort,
the recent-onset RA patients showed a stronger relation-
ship between CXCL13 and IgG ACPA with P = 0.006
(r = 0.21) (Figure 3D) and P = 0.02 by tertile analysis (data
not shown), respectively, but no relationship between
serum IgG and CXCL13 level was observed (r = 0.11,13 to high-sensitivity C-reactive protein or disease activity score
outh RA Cohort and the Sherbrooke Early Undifferentiated
of log-transformed C-X-C motif chemokine 13 (LogCXCL13) and
123, P = 0.07). (B) In the Dartmouth RA Cohort, correlation analysis of
(DAS28-CRP) (n = 23, P = 0.01). (C) In the recent-onset rheumatoid
(EUPA) Cohort, no relationship is identified between LogCXCL13 and
brooke EUPA Cohort, no relationship is identified between LogCXCL13
Figure 3 Scatterplots demonstrate serum CXCL13 strongly correlates with seropositive rheumatoid arthritis and immunoglobulin M
rheumatoid factor levels in the Sherbrooke Early Undifferentiated PolyArthritis Cohort, but has a weaker relationship to anticitrullinated
peptide/protein antibody levels. (A) Log-transformed C-X-C motif chemokine 13 (LogCXCL13) is higher in seropositive than in seronegative RA
patients as determined by t-test (seropositive: n = 173, geometric mean (95% CI) = 323.6 pg/ml (223.9 to 477.5); seronegative: n = 166, geometric
mean (95% CI) = 50.1 pg/ml (35.0 to 78.0); P < 0.0001). (B) As with the Dartmouth RA Cohort, a strong relationship is seen with LogCXCL13 and
immunoglobulin M rheumatoid factor (IgM RF) in seropositive samples, whether measured by Spearman correlation (P < 0.0001) (C) or by CXCL13
tertile analysis (third-tertile mean RF = 223 ± 57 IU/ml, first- and second-tertile mean RF = 141 ± 75 IU/ml; P < 0.0001). (D) A significant relationship is
found between CXCL13 and anticitrullinated peptide/protein antibody (ACPA) by Spearman correlation (P = 0.006). *P < 0.05. Diagonal lines represent
lines of best fit.
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Dartmouth RA Cohort, we found no relationship with
shared epitope status in the seropositives (n = 132; P =
0.38) (data not shown) or with smoking status (P = 0.62).
Additionally, when we combined the data set from both
cohorts, we continued to find no relationship with either
shared epitope or smoking status (Additional file 1).
Relationships between CXCL13 and disease activity
measures in an early rheumatoid arthritis cohort
The recent-onset RA patients drawn from the Sherbrooke
EUPA Cohort showed no association between log CXCL13
serum levels and either age or sex (P = 0.77 and P = 0.43
respectively) (data not shown). A correlation between log
CXCL13 and log CRP values were identified when sero-
positive and seronegative patients were combined (n = 339;
r = 0.14, P = 0.01) (data not shown). This association dis-
sipated when evaluated only in the seropositives (n = 173;
r = 0.13, P = 0.08) (Figure 2C). A similar relationship of
serum CXCL13 to DAS28-CRP levels was shown in all pa-
tients (n = 335; r = 0.12, P = 0.02), but this association also
went away when the analysis was limited to seropositives
(n = 170; r = 0.08, P = 0.28) (Figure 2D). There was no re-
lationship between log CXCL13 levels and the presence of
erosions at baseline in seropositive patients, regardless ofwhether it was evaluated by Spearman correlation accor-
ding to number of erosions (n = 123; r = −0.12, P = 0.17)
(data not shown) or by t-test to compare the presence or
absence of erosions (0 vs ≥1 erosions, P = 0.34; <5 vs ≥5
erosions; P = 0.95).
Relationships between serum CXCL13 and
immunoglobulin A rheumatoid factor
Despite a strong relationship of serum CXCL13 with IgM
RF seropositivity, both established and recent-onset RA
cohorts exhibited weaker correlations between CXCL13
and serum IgG and IgG ACPA levels. These data suggest
that elevated serum CXCL13 levels might correspond to a
process in which non-class-switched B cells producing
IgM RF were promoted independently of follicle and ger-
minal center formation that leads to immunoglobulin
heavy-chain class switching and IgG ACPA. To begin to
address this model, we analyzed the relationship between
serum CXCL13 levels and IgA RF.
Analysis of log-transformed CXCL13 and log-trans-
formed IgA RF in the seropositive patients of both co-
horts were strongly correlated (P < 0.0001) (Figure 4A
and 4C). When evaluated by CXCL13 tertile analysis,
the highest tertile had much higher IgA RF values than
the first and second tertiles in the Dartmouth RA Cohort
Figure 4 Scatterplots illustrate a strong relationship of serum CXCL13 with immunoglobulin A rheumatoid factor in seropositive
rheumatoid arthritis patients in both the Dartmouth RA Cohort (established RA) and recent-onset rheumatoid arthritis patients from
the Sherbrooke Early Undifferentiated PolyArthritis Cohort. (A) Pearson correlation analysis of log-transformed C-X-C motif chemokine 13
(LogCXCL13) values and log-transformed immunoglobulin A rheumatoid factor (Log IgA RF) in the Dartmouth RA Cohort shows a strong association
(P < 0.0001). (B) CXCL13 tertile analysis confirms this relationship (third-tertile IgA RF: geometric mean (95% CI) = 45.0 IU/ml (28.0 to 72.3), first- and
second-tertile IgA RF: geometric mean (95% CI) = 11.2 IU/ml (7.6 to 16.3); P < 0.0001). (C) In the Sherbrooke Early Undifferentiated PolyArthritis Cohort,
the relationship between LogCXCL13 and Log IgA RF persists, whether measured by correlation (P < 0.0001) (D) or by CXCL13 tertile analysis
(third-tertile IgA RF: geometric mean (95% CI) = 74.1 IU/ml (51.4 to 106.7), first- and second-tertile IgA RF: geometric mean (95% CI) = 20.4 IU/ml
(15.1 to 27.5); P < 0.0001). *P < 0.05. Diagonal lines represent lines of best fit.
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72.3), first- and second-tertile geometric mean (95% CI)
11.2 IU/ml (7.6 to 16.3); P < 0.0001) (Figure 4B). A simi-
larly strong correlation was seen in recent-onset, mostly
untreated RA patients (third-tertile geometric mean (95%
CI) 74.1 IU/ml (51.4 to 106.7), first- and second-tertile
geometric mean (95% CI) 20.4 IU/ml (15.1 to 27.5); P <
0.0001) (Figure 4D). Thus, serum CXCL13 levels exhibited
strong correlations with both IgM and IgA RF titers.
Discussion
We report a strong relationship between elevated serum
CXCL13 levels and seropositive RA that was seen in an
established disease cohort and confirmed in a mostly un-
treated early RA cohort. Modest associations were seen
with disease activity measures in established RA, but no
associations were present in patients with early disease.
We did not find any evidence to support a relationship
between CXCL13 and HLA-DRB1 alleles containing the
shared epitope or complement C4B deficiency. The most
striking finding was the strength of the relationship bet-
ween serum CXCL13 with IgM and IgA RF relative to
that seen with ACPA titers (Figures 1, 3 and 4), an ob-
servation not due to the heterophilic effects of RF.Although an association between CXCL13 and ACPA
was observed, it was not as strong a relationship as that
seen with RF (IgM RF: r = 0.45 and r = 0.54 in the estab-
lished and early RA cohorts, respectively; IgG ACPA: r =
0.17 and r = 0.21, respectively). These observations sug
gest interesting and potentially specific associations of
CXCL13 with both RF autoantibody formation and the
pathogenesis of RA.
We evaluated patients with very high CXCL13 values
(top decile) and did not observe any significant variation
in RF or ACPA values compared with the remaining pa-
tients in the highest tertile (data not shown). Further, we
did not identify any competing diagnosis (for example,
lymphoma or cryoglobulinemia) or therapy to account
for the very high levels of CXCL13.
The presence of elevated CXCL13 levels in seropo-
sitive patients from two distinct cohorts composed of
patients with established and recent-onset RA suggests
that this abnormality may be maintained over the course
of the disease and may not be extensively influenced by
disease duration or prior therapy. Supporting this notion
is our observation that the mean CXCL13 levels in the
two cohorts were nearly identical (330 vs 323 pg/ml). By
extension, this result would predict the absence of a
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measures. Indeed, only a modest relationship with
DAS28-CRP, and no relationship with hsCRP or CDAI,
was seen in the Dartmouth RA Cohort. In addition, no re-
lationship was observed with baseline hsCRP, DAS28-CRP
or radiographic erosions in the recent-onset RA patients
from the Sherbrooke EUPA Cohort (Figure 2A to 2D).
Similar findings (modest correlation with DAS28-CRP
and no correlation with erosive disease) were recently
reported in a French cross-sectional cohort [16]. Thus,
elevated serum CXCL13 levels did not simply reflect
quantitative differences in synovial or systemic inflamma-
tion between patients; rather, these data suggest the pre-
sence of a qualitatively distinct subset of seropositive RA
manifested by specific increases in both IgM and IgA RF.
This interpretation is further supported by the findings
reported in a small study (n = 20) demonstrating that
serum CXCL13 levels did not correlate with DAS28
measures [11]. Perhaps more important, the same study
identified a strong relationship between serum CXCL13
protein and synovial CXCL13 mRNA expression [11].
Thus, serum CXCL13 levels appear to derive from a syn-
ovial inflammation process characterized by the pro-
duction of CXCL13. Although this interpretation differs
somewhat from prior reports, these latter studies may
have been confounded by inclusion of seronegative pa-
tients or the inappropriate use of RF level as a criterion
for disease activity [11,17,18]. Clearly, additional studies
are needed to clarify this issue.
Murine models indicate that the function of CXCL13–
CXCR5 interactions promotes recruitment of B cells and
follicular T helper cells to the follicle and germinal cen-
ters in secondary lymphoid organs [19]. In humans, the
precise role of CXCL13, let alone rheumatoid synovium,
is less clear. Synovial expression of CXCL13 has been as-
sociated with diffuse lymphoid infiltration as well as the
presence of lymphoid aggregates that resemble germinal
centers [7,9,20]. However, the relationship of synovial
histology to either inflammation or autoantibody pro-
duction remains controversial [3,21,22].
The surprisingly strong correlation between serum
CXCL13 levels and RF (IgM and IgA) titers, relative to
that seen with either serum IgG or IgG-ACPA levels, in
both an established RA cohort and a recent-onset, mostly
untreated RA cohort may clarify the role of CXCL13 in
autoantibody production. A similar but lesser relationship
was observed in a recent cross-sectional analysis [16]. The
most straightforward interpretation is that a greater pro-
portion of circulating RF derives from synovial production
relative to IgG-ACPA and IgG, which are presumably pro-
duced at other sites, including the bone marrow. Despite
its simplicity, this model must account for why both IgM
RF and its class-switched counterpart, IgA RF, are affected.
Alternatively, high levels of CXCL13 production mayreflect a pathologic process in which synovial plasma cell
production of RF is selectively enhanced relative to ACPA
or other IgGs. Indeed, a strong CXCL13–RF relationship
does not establish causality; therefore, another possibility
is that elevated RF levels somehow drive increased pro-
duction of CXCL13.
Conclusion
In our present report, we demonstrate that serum levels of
the B-cell chemokine CXCL13 exhibit a strong relation-
ship with seropositive RA. The nature of this correlation
appears to be particularly strong for both IgM and IgA RF,
whereas there is a weaker relationship with IgG-ACPA. A
particular strength of this finding is its presence to nearly
identical degrees in both an early RA cohort and an estab-
lished RA cohort. Elevations of serum CXCL13 did not
consistently associate with disease duration, sex or mea-
sures of disease activity in seropositive RA patients. More-
over, CXCL13 levels did not appear to associate with
other features of seropositivity, such as the shared epitope.
These results suggest that elevated CXCL13 levels may
possibly be used to identify a distinct subset of seroposi-
tive RA patients that may either promote or result from
the expansion of RF-producing B cells.
Additional file
Additional file 1: Figure S1. Evaluation of combined data from
seropositive patients from the Dartmouth and Sherbrooke cohorts. The
evaluation did not identify any relationship with shared epitope status or
smoking. (A) Log C-X-C motif chemokine 13 (CXCL13) levels do not vary
based on the presence or absence of the shared epitope (n = 258, P = 0.73).
(B) Log CXCL13 levels have no relationship with smoking whether comparing
current smokers (n = 80) to past smokers (n = 129; P = 0.69), current smokers
to never-smokers (n = 125; P = 0.28) or current smokers to both past and
never-smokers (P = 0.42).
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